Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)

American Journal of Cardiology

Volumn 119, Issue 1, 2017, Pages 40-46

  Gaudet, Daniel ^a   Watts, Gerald F ^b   Robinson, Jennifer G ^c   Minini, Pascal ^d   Sasiela, William J ^e   Edelberg, Jay ^d   Louie, Michael J ^e   Raal, Frederick J ^f  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF IOWA   (United States)

^d SANOFI   (France)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EZETIMIBE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENDER; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; RANDOMIZED CONTROLLED TRIAL; BIOASSAY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84994051920     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.09.010     Document Type: Article

References (26)

1. 1 Bays, H., Gaudet, D., Weiss, R., Ruiz, J.L., Watts, G.F., Gouni-Berthold, I., Robinson, J., Zhao, J., Hanotin, C., Donahue, S., Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab 100 (2015), 3140–3148.
2. 2 Cannon, C.P., Cariou, B., Blom, D., McKenney, J.M., Lorenzato, C., Pordy, R., Chaudhari, U., Colhoun, H.M., Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 36 (2015), 1186–1194.
3. 3 Farnier, M., Jones, P., Severance, R., Averna, M., Steinhagen-Thiessen, E., Colhoun, H.M., Du, Y., Hanotin, C., Donahue, S., Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis 244 (2016), 138–146.
4. 4 Kastelein, J.J., Ginsberg, H.N., Langslet, G., Hovingh, G.K., Ceska, R., Dufour, R., Blom, D., Civeira, F., Krempf, M., Lorenzato, C., Zhao, J., Pordy, R., Baccara-Dinet, M.T., Gipe, D.A., Geiger, M.J., Farnier, M., ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 36 (2015), 2996–3003.
5. 5 Ginsberg, H.N., Rader, D.J., Raal, F.J., Guyton, J.R., Baccara-Dinet, M.T., Lorenzato, C., Pordy, R., Stroes, E., Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dL or higher. Cardiovasc Drugs Ther 30 (2016), 473–483.
6. 6 Kereiakes, D.J., Robinson, J.G., Cannon, C.P., Lorenzato, C., Pordy, R., Chaudhari, U., Colhoun, H.M., Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J 169 (2015), 906–915.e913.
7. 7 Moriarty, P.M., Thompson, P.D., Cannon, C.P., Guyton, J.R., Bergeron, J., Zieve, F., Bruckert, E., Jacobson, T.A., Kopecky, S.L., Baccara-Dinet, M.T., Du, Y., Gipe, D., Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin-re-challenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 9 (2015), 758–769.
8. 8 Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., El, S.M., Koren, M.J., Lepor, N.E., Lorenzato, C., Pordy, R., Chaudhari, U., Kastelein, J.J., Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
9. 9 Roth, E.M., Taskinen, M.R., Ginsberg, H.N., Kastelein, J.J., Colhoun, H.M., Robinson, J.G., Merlet, L., Pordy, R., Baccara-Dinet, M.T., Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 176 (2014), 55–61.
10. 10 Gaudet, D., Kereiakes, D.J., McKenney, J.M., Roth, E.M., Hanotin, C., Gipe, D., Du, Y., Ferrand, A.C., Ginsberg, H.N., Stein, E.A., Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 114 (2014), 711–715.
11. 11 Erqou, S., Kaptoge, S., Perry, P.L., Di, A.E., Thompson, A., White, I.R., Marcovina, S.M., Collins, R., Thompson, S.G., Danesh, J., Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009), 412–423.
12. 12 Kamstrup, P.R., Tybjaerg-Hansen, A., Nordestgaard, B.G., Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63 (2014), 470–477.
13. 13 Jacobson, T.A., Ito, M.K., Maki, K.C., Orringer, C.E., Bays, H.E., Jones, P.H., McKenney, J.M., Grundy, S.M., Gill, E.A., Wild, R.A., Wilson, D.P., Brown, W.V., National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol 9 (2015), 129–169.
14. 14 Nordestgaard, B.G., Chapman, M.J., Ray, K., Boren, J., Andreotti, F., Watts, G.F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O.S., Fisher, E., Kovanen, P.T., Kuivenhoven, J.A., Lesnik, P., Masana, L., Reiner, Z., Taskinen, M.R., Tokgozoglu, L., Tybjaerg-Hansen, A., Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31 (2010), 2844–2853.
15. 15 Bos, S., Yayha, R., van Lennep, J.E., Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol 25 (2014), 452–460.
16. 16 Kasssner, U., Schlabs, T., Rosada, A., Steinhagen-Thiessen, E., Lipoprotein(a)–An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl 18 (2015), 263–267.
17. 17 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., Wiklund, O., Hegele, R.A., Raal, F.J., Defesche, J.C., Wiegman, A., Santos, R.D., Watts, G.F., Parhofer, K.G., Hovingh, G.K., Kovanen, P.T., Boileau, C., Averna, M., Boren, J., Bruckert, E., Catapano, A.L., Kuivenhoven, J.A., Pajukanta, P., Ray, K., Stalenhoef, A.F., Stroes, E., Taskinen, M.R., Tybjaerg-Hansen, A., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34 (2013), 3478a–3490a.
18. 18 Seidah, N.G., Prat, A., The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11 (2012), 367–383.
19. 19 Romagnuolo, R., Scipione, C.A., Boffa, M.B., Marcovina, S.M., Seidah, N.G., Koschinsky, M.L., Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 290 (2015), 11649–11662.
20. 20 Stein, E.A., Honarpour, N., Wasserman, S.M., Xu, F., Scott, R., Raal, F.J., Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128 (2013), 2113–2120.
21. 21 Koschinsky, M., Gemin, M., Scipione, C., Boffa, M., Seidah, N., Romagnuolo, R., Evaluating the roles of PCSK9 and specific receptors in lipoprotein(a) catabolism. J Clin Lipidol 10 (2016), 720–721.
22. 22 Kurt, B., Soufi, M., Sattler, A., Schaefer, J.R., Lipoprotein(a)-clinical aspects and future challenges. Clin Res Cardiol Suppl 10 (2015), 26–32.
23. 23 Guo, Y.L., Zhang, W., Li, J.J., PCSK9 and lipid lowering drugs. Clin Chim Acta 437 (2014), 66–71.
24. 24 Khera, A.V., Qamar, A., Reilly, M.P., Dunbar, R.L., Rader, D.J., Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol 115 (2015), 178–182.
25. 25 Raal, F.J., Giugliano, R.P., Sabatine, M.S., Koren, M.J., Blom, D., Seidah, N.G., Honarpour, N., Lira, A., Xue, A., Chiruvolu, P., Jackson, S., Di, M., Peach, M., Somaratne, R., Wasserman, S.M., Scott, R., Stein, E.A., PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res 57 (2016), 1086–1096.
26. 26 Teramoto, T., Kobayashi, M., Tasaki, H., Yagyu, H., Higashikata, T., Takagi, Y., Uno, K., Baccara-Dinet, M.T., Nohara, A., Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins- ODYSSEY Japan randomized controlled trial. Circ J 80 (2016), 1980–1987.